Drug Approval | January 05, 2025
CDSCO approves Wockhardt’s Mignaf for treatment of community acquired bacterial pneumonia
Wockhardt plans to launch Miqnaf in the Indian market in coming few months
Wockhardt plans to launch Miqnaf in the Indian market in coming few months
Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia
Final decision from the European Commission is anticipated within the coming months
The trademark rights for these brands will be transferred to Lupin by March next year.
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
Union Government will provide a health cover of Rs. 5 lakh to any elderly person above 70 years of age
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
Subscribe To Our Newsletter & Stay Updated
